Sign in
TerminatedPhase 1

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects

Key facts

Who runs it
Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
33 people enrolled
Started
25 Nov 2025
Ended
21 Aug 2026
Type of study
Interventional, 9 groups
Treatments tested
  • TQC3302 inhalation spray
  • TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation
  • Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray
  • Budesonide Powder for Inhalation+ TQC3302 inhalation spray+ Tiotropium bromide and olodaterol hydrochloride inhalation spray
Record updated
27 August 2026
Why it stopped
This study shall be terminated as a result of strategic adjustments to the company-sponsored research and development of TQC3302 Inhalation Spray.

Who can take part

Age
18 years to 55 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Subjects voluntarily joined the study, sign informed consent form before the study and fully understand the study content
  • Healthy subjects aged between 18 and 55 years (inclusive),both male and female
  • The male subject should weigh at least 50kg, the female subject should weigh at least 45kg. And body mass index (BMI) within 19~28 kg/m2
  • Inhalation administration training qualified
  • During the screening period, the percentage of predicted value for forced expiratory volume in one second (FEV1) before bronchodilator administration is ≥80%, and FEV1/forced vital capacity (FVC) is ≥70%
  • Have no pregnancy plan and voluntarily take effective contraception measures from time of screening to at least 90 days after the last dose (subjects and their partners)

Who cannot take part

  • People who have received or are planning to receive inactive or active vaccines during the 30 days prior to the screening period and the entire study period
  • Had undergone surgery within 1 month prior to screening period or expected to undergo surgery during the study period
  • Individuals with a history of glaucoma, functional constipation, benign prostatic hyperplasia, urinary tract obstruction, etc
  • Current history of active tuberculosis, bronchiectasis or other non-specific lung diseases
  • Any history of drug allergies, Individuals with a specific history of allergies or allergies
  • People who have potential difficulty in blood collection, or have a history of halo needles or blood sickness;
  • History of drug or narcotics abuse or a positive result of urine drug test at screening
  • Subjects Positive for Any of Hepatitis B Virus Surface Antigen (HBsAg), Hepatitis C Virus Antibody (Anti-HCV), Human Immunodeficiency Virus Antibody (Anti-HIV), and Treponema Pallidum Antibody (Anti-TP)
  • People who have abnormal and clinically significant results in vital signs, physical examination, laboratory tests, Chest radiograph and abdominal ultrasound during screening period
  • People with special dietary requirements who cannot follow a standard diet
  • Pregnant or lactating women or those with positive blood pregnancy test results during the screening period

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Groups 1, 3, 4, 5 and 6 of this research team adopted a single-center, open-label design. Group 2 used a three-sequence, three-period crossover design, where participants in this dose group were randomly assigned to the three sequences in a 1:1:1 ratio to undergo three-period crossover administration. Healthy adult subjects were selected to use TQC3302 inhalation spray to evaluate the safety, tolerability, and pharmacokinetic characteristics of single and multiple inhalations of TQC3302 inhalation spray in healthy participants.

The 9 groups in the trial

  • TQC3302 inhalation spray (50/2.5/2.5μg)Treatment being tested

    Administered as a single dose

    Treatment: TQC3302 inhalation spray

  • TQC3302/Spiolto® Respimat® /Pulmicort®Treatment being tested

    Each drug is administered as a single dose. TQC3302 inhalation spray (200/2.5/2.5μg); Spiolto® Respimat® : Tiotropium bromide and olodaterol hydrochloride inhalation spray (2.5/2.5μg); Pulmicort® : Budesonide Powder for Inhalation (200μg)

    Treatment: TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation

  • Pulmicort®/Spiolto® Respimat®Treatment being tested

    Each drug is administered as a single dose. Spiolto® Respimat®: Tiotropium bromide and olodaterol hydrochloride inhalation spray (2.5/2.5μg) ; Pulmicort®: Budesonide Powder for Inhalation (200μg) TQC3302 inhalation spray (200/2.5/2.5μg)

    Treatment: Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray

  • Spiolto® Respimat® /Pulmicort®/TQC3302Treatment being tested

    Each drug is administered as a single dose. Pulmicort®: Budesonide Powder for Inhalation (200μg); TQC3302 inhalation spray (200/2.5/2.5μg); Spiolto® Respimat®: Tiotropium bromide and olodaterol hydrochloride inhalation spray (2.5/2.5μg)

    Treatment: Budesonide Powder for Inhalation+ TQC3302 inhalation spray+ Tiotropium bromide and olodaterol hydrochloride inhalation spray

  • TQC3302 inhalation spray (200/5/5μg)-single doseTreatment being tested

    TQC3302 inhalation spray is administered as a single dose.

    Treatment: TQC3302 inhalation spray

  • TQC3302 inhalation spray (400/5/5μg)Treatment being tested

    TQC3302 inhalation spray is administered as a single dose

    Treatment: TQC3302 inhalation spray

  • TQC3302 inhalation spray (200/5/5μg)Treatment being tested

    Single dose during Day 1-Day 7

    Treatment: TQC3302 inhalation spray

  • TQC3302 inhalation spray (400/5/5μg)-single doseTreatment being tested

    single dose during Day 1-Day 7

    Treatment: TQC3302 inhalation spray

  • TQC3302 inhalation spray (400/5/5μg) -two doseTreatment being tested

    Two dose during Day 1-Day 7

    Treatment: TQC3302 inhalation spray

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects in China
Record updated
27 August 2026